Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475386 | 0.85 | CHEK1 (0.56) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5475886 | 0.83 | CHEK1 (0.52) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5465172 | 0.83 | CHEK1 (0.48) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5470235 | 0.83 | JAK1 (0.39) | CHEK1ALDH1A1 | |
| SCHEMBL14492135 | 0.83 | CHEK1 (0.60) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5497035 | 0.81 | CHEK1 (0.62) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5470805 | 0.80 | CHEK1 (0.47) | CHEK1ALDH1A1MAP3K7JAK2KDR | |
| SCHEMBL5476487 | 0.80 | CHEK1 (0.44) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5480654 | 0.79 | CHEK1 (0.49) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5470777 | 0.78 | CHEK1 (0.44) | CHEK1MAP3K7JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885ALDH1A1 1270/4885CYP1A2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.